Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
BMC Musculoskeletal Disorders
Published in: BMC Musculoskeletal Disorders 1/2013

Open Access 01-12-2013 | Research article

Differences in osteogenic and apoptotic genes between osteoporotic and osteoarthritic patients

Authors: Mercè Giner, Mª José Montoya, Mª Angeles Vázquez, Cristina Miranda, Ramón Pérez-Cano

Published in: BMC Musculoskeletal Disorders | Issue 1/2013

Login to get access

Abstract

Background

Osteoporosis is a metabolic disorder characterized by a reduction in bone mass and deterioration in the microarchitectural structure of the bone, leading to a higher risk for spontaneous and fragility fractures.
The main aim was to study the differences between human bone from osteoporotic and osteoarthritic patients about gene expression (osteogenesis and apoptosis), bone mineral density, microstructural and biomechanic parameters.

Methods

We analyzed data from 12 subjects: 6 with osteoporotic hip fracture (OP) and 6 with hip osteoarthritis (OA), as the control group. All subjects underwent medical history, analytical determinations, densitometry, histomorphometric and biochemical study. The expression of 86 genes of osteogenesis and 86 genes of apoptosis was studied in pool of bone samples from patients with OP and OA by PCR array.

Results

We observed that most of the genes of apoptosis and osteogenesis show a decrease in gene expression in the osteoporotic group in comparison with the osteoarthritic group. The histomorphometric study shows a lower bone quality in the group of patients with hip fractures compared to the osteoarthritic group.

Conclusions

The bone tissue of osteoporotic fracture patients is more fragile than the bone of OA patients. Our results showed an osteoporotic bone with a lower capacities for differentiation and osteoblastic activity as well as a lower rate of apoptosis than osteoarthritic bone. These results are related with structural and biochemical parameters.
Appendix
Available only for authorised users
Literature
1.
2.
Jemtland R, Holden M, Reppe S, Olstad OK, Reinholt FP, Gautvik VT, Refvem H, Frigessi A, Houston B, Gautvik KM: Molecular disease map of bone characterizing the postmenopausal osteoporosis phenotype. J Bone Miner Res. 2011, 26 (8): 1793-1801. 10.1002/jbmr.396.CrossRefPubMed
3.
Javed A, Chen H, Ghori FY: Genetic and transcriptional control of bone formation. Oral Maxillofac Surg Clin North Am. 2010, 22 (3): 283-293. 10.1016/j.coms.2010.05.001.CrossRefPubMedPubMedCentral
4.
Velasco J, Zarrabeitia MT, Prieto JR, Perez-Castrillon JL, Perez-Aguilar MD, Perez-Nuñez MI, Sañudo C, Hernandez-Elena J, Calvo I, Ortiz F, Gonzalez-Macias J, Riancho JA: Wnt pathway genes in osteoporosis and osteoarthritis: differential expression and genetic association study. Osteoporos Int. 2010, 21 (1): 109-118. 10.1007/s00198-009-0931-0.CrossRefPubMed
5.
Zelzer E, Olsen BR: Multiple roles of vascular endothelial growth factor (VEGF) in skeletal development, growth, and repair. Curr Top Dev Biol. 2005, 65: 169-187.CrossRefPubMed
6.
Kim SJ, Kim SY, Kwon CH: Differential effect of FGF and PDGF on cell proliferation and migration in osteoblastic cells. Growth Factors. 2007, 25 (2): 77-86. 10.1080/08977190701398977.CrossRefPubMed
7.
Kearns AE, Khosla S, Kostenuik PJ: Receptor activator of nuclear factor kappaB ligand and osteoprotegerin regulation of bone remodeling in health and disease. Endocr Rev. 2008, 29 (2): 155-192.CrossRefPubMed
8.
Hock JM, Krishnan V, Onyia JE, Bidwell JP, Milas J, Stanislaus D: Osteoblast apoptosis and bone turnover. J Bone Miner Res. 2001, 16 (6): 975-984. 10.1359/jbmr.2001.16.6.975.CrossRefPubMed
9.
Moriishi T, Maruyama Z, Fukuyama R, Ito M, Miyazaki T, Kitaura H, Ohnishi H, Furuichi T, Kawai Y, Masuyama R, Komori H, Takada K, Kawaguchi H, Komori T: Overexpression of Bcl2 in osteoblasts inhibits osteoblast differentiation and induces osteocyte apoptosis. PLoS One. 2011, 6 (11): e27487-10.1371/journal.pone.0027487.CrossRefPubMedPubMedCentral
10.
Cano A, Dapía S, Noguera I: Comparative effects of 17beta-estradiol, raloxifene and genistein on bone 3D microarchitecture and volumetric bone mineral density in the ovariectomized mice. Osteoporos Int. 2008, 19 (6): 793-800. 10.1007/s00198-007-0498-6.CrossRefPubMed
11.
Wang B, Wood IS, Trayhurn P: PCR arrays identify metallothionein-3 as a highly hypoxia-inducible gene in human adipocytes. Biochem Biophys Res Commun. 2008, 368 (1): 88-93. 10.1016/j.bbrc.2008.01.036.CrossRefPubMedPubMedCentral
12.
Hopwood B, Tsykin A, Findlay DM, Fazzalari NL: Gene expression profile of the bone microenvironment in human fragility fracture bone. Bone. 2009, 44 (1): 87-101. 10.1016/j.bone.2008.08.120.CrossRefPubMed
13.
Dragojevič J, Logar DB, Komadina R, Marc J: Osteoblastogenesis and adipogenesis are higher in osteoarthritic than in osteoporotic bone tissue. Arch Med Res. 2011, 42 (5): 392-397. 10.1016/j.arcmed.2011.08.005.CrossRefPubMed
14.
Napal J, Amado JA, Riancho JA, Olmos JM, González-Macías J: Stress decreasesthe serum level of osteocalcin. Bone Miner. 1993, 21 (2): 113-118. 10.1016/S0169-6009(08)80013-X.CrossRefPubMed
15.
Kumarasinghe DD, Hopwood B, Kuliwaba JS, Atkins GJ, Fazzalari NL: An update on primary hip osteoarthritis including altered Wnt and TGF-β associated gene expression from the bony component of the disease. Rheumatology (Oxford). 2011, 50 (12): 2166-2175. 10.1093/rheumatology/ker291.CrossRef
16.
Kumarasinghe DD, Perilli E, Tsangari H, Truong L, Kuliwaba JS, Hopwood B, Atkins GJ, Fazzalari NL: Critical molecular regulators, histomorphometric indices and their correlations in the trabecular bone in primary hip osteoarthritis. Osteoarthr Cartil. 2010, 18 (10): 1337-1344. 10.1016/j.joca.2010.07.005.CrossRefPubMed
17.
Kaji H, Naito J, Sowa H: Smad3 differently affects osteoblast differentiation depending upon its differentiation stage. Horm Metab Res. 2006, 38 (11): 740-745. 10.1055/s-2006-955085.CrossRefPubMed
18.
Cunningham NS, Paralkar V, Reddi AH: Osteogenin and recombinant bone morphogenetic protein 2B are chemotactic for human monocytes and stimulate transforming growth factor beta 1 mRNA expression. Proc Natl Acad Sci USA. 1992, 89 (24): 11740-11744. 10.1073/pnas.89.24.11740.CrossRefPubMedPubMedCentral
19.
Zhu F, Friedman MS, Luo W: The transcription factor osterix (SP7) regulates BMP6-induced human osteoblast differentiation. J Cell Physiol. 2012, 227 (6): 2677-2685. 10.1002/jcp.23010.CrossRefPubMedPubMedCentral
20.
Snelling SJB, Hulley PA, Loughlin J: BMP5 activates multiple signaling pathways and promotes chondrogenic differentiation in the ATDC5 growth plate model. Growth Factors. 2010, 28 (4): 268-279. 10.3109/08977191003752296.CrossRefPubMed
21.
García S, Forteza J, López-Otin C: Matrix metalloproteinase-8 deficiency increases joint inflammation and bone erosion in the K/BxN serum-transfer arthritis model. Arthritis Res Ther. 2010, 12 (6): R224-10.1186/ar3211.CrossRefPubMedPubMedCentral
22.
Zupan J, Komadina R, Marc J: The relationship between osteoclastogenic and anti-osteoclastogenic pro-inflammatory cytokines differs in human osteoporotic and osteoarthritic bone tissues. J Biomed Sci. 2012, 1: 19-28.
23.
Zhu J, Shimizu E, Zhang X: EGFR signaling suppresses osteoblast differentiation and inhibits expression of master osteoblastic transcription factors Runx2 and Osterix. J Cell Biochem. 2011, 112 (7): 1749-1760. 10.1002/jcb.23094.CrossRefPubMedPubMedCentral
24.
Feito MJ, Lozano RM, Alcaide M: Immobilization and bioactivity evaluation of FGF-1 and FGF-2 on powdered silicon-doped hydroxyapatite and their scaffolds for bone tissue engineering. J Mater Sci Mater Med. 2011, 22 (2): 405-416. 10.1007/s10856-010-4193-3.CrossRefPubMed
25.
Dunstan CR, Boyce R, Boyce BF: Systemic administration of acidic fibroblast growth factor (FGF-1) prevents bone loss and increases new bone formation in ovariectomized rats. J Bone Miner Res. 1999, 14 (6): 953-959. 10.1359/jbmr.1999.14.6.953.CrossRefPubMed
26.
Wang W, Li S, Niu D: Study on relationship between osteoporosis and mRNA expressions of vascular endothelial growth factor and bone morphogenetic protein 2 in nontraumatic avascular necrosis of femoral head. Zhongguo Xiu Fu Chong Jian Wai Ke Za Zhi. 2010, 24 (9): 1072-1077.PubMed
27.
Schultz DR, Harrington WJ: Apoptosis: programmed cell death at a molecular level. Semin Arthritis Rheum. 2003, 32 (6): 345-369. 10.1053/sarh.2003.50005.CrossRefPubMed
28.
van Kooten C, Banchereau J: CD40-CD40 ligand. J Leukoc Biol. 2000, 67 (1): 2-17.PubMed
29.
Blagosklonny MV: Cell death beyond apoptosis. Leukemia. 2000, 14 (8): 1502-1508. 10.1038/sj.leu.2401864.CrossRefPubMed
30.
Bran GM, Stern-Straeter J, Hörmann K: Apoptosis in bone for tissue engineering. Arch Med Res. 2008, 39 (5): 467-482. 10.1016/j.arcmed.2008.02.007.CrossRefPubMed
31.
32.
Delgado-Calle J, Arozamena J, García-Renedo R, García-Ibarbia C, Pascual-Carra MA, González-Macías J, Riancho JA: Osteocyte deficiency in hip fractures. Calcif Tissue Int. 2011, 89 (4): 327-334. 10.1007/s00223-011-9522-0.CrossRefPubMed
33.
Hofbauer LC, Gori F, Riggs BL: Stimulation of osteoprotegerin ligand and inhibition of osteoprotegerin production by glucocorticoids in human osteoblastic lineage cells: potential paracrine mechanisms of glucocorticoid-induced osteoporosis. Endocrinology. 1999, 140 (10): 4382-4389. 10.1210/en.140.10.4382.PubMed
34.
Weinstein RS, O’Brien CA, Almeida M: Osteoprotegerin prevents glucocorticoid-induced osteocyte apoptosis in mice. Endocrinology. 2011, 152 (9): 3323-3331. 10.1210/en.2011-0170.CrossRefPubMedPubMedCentral
35.
Shen Y, Zhang Z-M, Jiang S-D: Postmenopausal women with osteoarthritis and osteoporosis show different ultrastructural characteristics of trabecular bone of the femoral head. BMC Musculoskelet Disord. 2009, 10: 35-10.1186/1471-2474-10-35.CrossRefPubMedPubMedCentral
36.
Patsch JM, Kohler T, Berzlanovich A: Trabecular bone microstructure and local gene expression in iliac crest biopsies of men with idiopathic osteoporosis. J Bone Miner Res. 2011, 26 (7): 1584-1592. 10.1002/jbmr.344.CrossRefPubMed
Metadata
Title
Differences in osteogenic and apoptotic genes between osteoporotic and osteoarthritic patients
Authors
Mercè Giner
Mª José Montoya
Mª Angeles Vázquez
Cristina Miranda
Ramón Pérez-Cano
Publication date
01-12-2013
Publisher
BioMed Central
Published in
BMC Musculoskeletal Disorders / Issue 1/2013
Electronic ISSN: 1471-2474
DOI
https://doi.org/10.1186/1471-2474-14-41

Other articles of this Issue 1/2013

BMC Musculoskeletal Disorders 1/2013 Go to the issue

Research article

Bone turnover and bone mineral density in HIV-1 infected Chinese taking highly active antiretroviral therapy –a prospective observational study

Research article

Development of the young spine questionnaire

Research article

Reduced creatinine clearance is associated with early development of subcutaneous tophi in people with gout

Research article

Validation of an advanced practice physiotherapy model of care in an orthopaedic outpatient clinic

Study protocol

Design considerations of a randomized clinical trial on a cognitive behavioural intervention using communication and information technologies for managing chronic low back pain

Research article

Time course of 25(OH)D3 vitamin D3 as well as PTH (parathyroid hormone) during fracture healing of patients with normal and low bone mineral density (BMD)